Drug methylation in cancer therapy: Lessons from the TPMT polymorphism

Oncogene

Volumn 22, Issue 47 REV. ISS. 6, 2003, Pages 7403-7413

  Krynetski, Eugene ^a,b   Evans, William E ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Pharmacogenetics; Thiopurine S methyltransferase

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; AZATHIOPRINE; ENZYME VARIANT; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; MERCAPTOPURINE; NUCLEOTIDE DERIVATIVE; PRODRUG; THIOGUANOSINE MONOPHOSPHATE; THIOINOSINE MONOPHOSPHATE; THIOPURINE METHYLTRANSFERASE; TIOGUANINE; UNCLASSIFIED DRUG; XENOBIOTIC AGENT;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; BLOOD TOXICITY; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; DRUG ACCUMULATION; DRUG METABOLISM; ENTERITIS; ENZYME DEFICIENCY; ENZYME STABILITY; EXON; GENETIC CONSERVATION; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; HEMATOLOGIC DISEASE; HIGH RISK PATIENT; HUMAN; INTRON; LEUKEMIA; LIVER TOXICITY; METHYLATION; MOLECULAR GENETICS; NONHUMAN; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; PHARMACOGENETICS; PHARMACOGENOMICS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FUNCTION; RADIATION CARCINOGENESIS; REVIEW; RHEUMATIC DISEASE; SINGLE NUCLEOTIDE POLYMORPHISM; UNINDEXED SEQUENCE;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; EVOLUTION, MOLECULAR; HUMANS; METHYLATION; METHYLTRANSFERASES; MOLECULAR SEQUENCE DATA; NEOPLASMS; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 0242312707     PISSN: 09509232     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.onc.1206944     Document Type: Review

References (86)

1. Allan PW and Bennett Jr LL. (1971). Biochem. Pharmacol., 20, 847.
2. Alves S, Amorim A, Ferreira F and Prata MJ. (2001). Clin. Pharmacol. Ther., 70, 165-174.
3. Alves S, Prata MJ, Ferreira F and Amorim A. (1999). Pharmacogenetics, 9, 257-261.
4. Ando M, Ando Y, Hasegawa Y, Sekido Y, Shimokata K and Horibe K. (2001). Pharmacogenetics, 11, 269-273.
5. Bemi V, Turchi G, Margotti E, Giorgelli F, Pesi R, Sgarrella F, Tozzi MG and Camici M. (1999). Int. J. Cancer, 82, 556-561.
6. Black AJ, McLeod HL, Capell HA, Powrie RH, Matowe LK, Pritchard SC, Collie-Dusuid ES and Reid DM. (1998). Ann. Intern. Med., 129, 716-718.
7. Brouwer C, Marinaki AM, Lambooy LH, Duley JA, Shobowale-Bakre M and De Abreu RA. (2001). Leukemia, 15, 1792-1793.
8. Chen ZS, Lee K and Kruh GD. (2001). J. Biol. Chem., 276, 33747-33754.
9. Colombel JF, Ferrari N, Debuysere H, Marteau P, Gendre JP, Bonaz B, Soule JC, Modigliani R, Touze Y, Catala P, Libersa C and Broly F. (2000). Gastroenterology, 118, 1025-1030.
10. Coulthard SA, Howell C, Robson J and Hall AG. (1998). Blood, 92, 2856-2862.
11. Coulthard SA, Rabello C, Robson J, Howell C, Minto L, Middleton PG, Gandhi MK, Jackson G, McLelland J, O'Brien H, Smith S, Reid MM, Pearson AD and Hall AG. (2000). Br. J. Haematol., 110, 599-604.
12. Cournoyer B, Watanabe S and Vivian A. (1998). Biochim. Biophys. Acta, 1397, 161-168.
13. Deininger M, Szumlanski CL, Otterness DM, Van Loon J, Ferber W and Weinshilboum RM. (1994). Biochem. Pharmacol., 48, 2135-2138.
14. Dervieux T, Blanco JG, Krynetski EY, Vanin EF, Roussel MF and Relling MV. (2001). Cancer Res., 61, 5810-5816.
15. Elion GB. (1989). In Vitro Cell Dev. Biol., 25, 321-330.
16. Evans WE, Hon YY, Bomgaars L, Coutre S, Holdsworth M, Janco R, Kalwinsky D, Keller F, Khatib Z, Margolin J, Murray J, Quinn J, Ravindranath Y, Ritchey K, Roberts W, Rogers ZR, Schiff D, Steuber C, Tucci F, Kornegay N, Krynetski EY and Relling MV. (2001). J. Clin. Oncol., 19, 2293-2301.
17. Evans WE, Horner M, Chu YQ, Kalwinsky D and Roberts WM. (1991). J. Pediatr., 119, 985-989.
18. Evans WE and McLeod HL. (2002). N. Engl. J. Med. 348, 538-549.
19. Fessing MY, Belkov VM, Krynetski EY and Evans WE. (1998a). FEBS Lett., 424, 143-145.
20. Fessing MY, Krynetski EY, Zambetti GP and Evans WE. (1998b). Eur. J. Biochem., 256, 510-517.
21. Foster AP, Shaw SE, Duley JA, Shobowale-Bakre EM and Harbour DA. (2000). J. Vet. Intern. Med., 14, 552-554.
22. Hassoun BS, Palmer IS and Dwivedi C. (1995). Res. Commun. Mol. Pathol. Pharmacol., 90, 133-142.
23. Hill DL and Bennett Jr LL. (1969). Biochemistry, 8, 122-130.
24. Hon YY, Fessing M, Pui CH, Relling MV, Krynetski EY and Evans WE. (1999). Human Mol. Genet., 8, 371-376.
25. Ingman M, Kaessmann H, Paabo S and Gyllensten U. (2000). Nature, 408, 708-713.
26. Ishioka S, Hiyama K, Sato H, Yamanishi Y, McLeod HL, Kumagai K, Maeda H and Yamakido M. (1999). Intern. Med., 38, 944-947.
27. Jang IJ, Shin SG, Lee KH, Yim DS, Lee MS, Koo HH, Kim HK and Sohn DR. (1996). Br. J. Clin. Pharmacol., 42, 638-641.
28. Jinnah HA and Friedmann T. (2000). The Metabolic and Molecular Bases of Inherited Disease. CR Scriver, AL Beaudet, WS Sly and D Valle (eds). McGraw-Hill: New York.
29. Krynetski EY and Evans WE. (1998). Am. J. Hum. Genet., 63, 11-16.
30. Krynetski EY and Evans WE. (1999). Anticancer Drug Toxicity. HP Lipp (ed.). Marcel Dekker, Inc: New York, pp. 392-429.
31. Krynetski EY and Evans WE. (2000). Pharmacology, 61, 136-146.
32. Krynetski EY, Fessing MY, Yates CR, Sun D, Schuetz JD and Evans WE. (1997). Pharm. Res., 14, 1672-1678.
33. Krynetski EY, Krynetskaia NF, Yanishevski Y and Evans WE. (1995a). Mol. Pharmacol., 47, 1141-1147.
34. Krynetski EY, Schuetz JD, Galpin AJ, Pui CH, Relling MV and Evans WE. (1995b). Proc. Natl. Acad. Sci. USA, 92, 949-953.
35. Kubota T and Chiba K. (2001). Br. J. Clin. Pharmacol., 51, 475-477.
36. Kumagai K, Hiyama K, Ishioka S, Sato H, Yamanishi Y, McLeod HL, Konishi F, Maeda H and Yamakido M. (2001). Pharmacogenetics, 11, 275-278.
37. Lennard L, Lilleyman JS, Van Loon J and Weinshilboum RM. (1990). Lancet, 336, 225-229.
38. Lennard L, Van Loon JA, Lilleyman JS and Weinshilboum RM. (1987). Clin. Pharmacol. Ther., 41, 18-25.
39. Liu M, Turner RJ, Winstone TL, Saetre A, Dyllick-Brenzinger M, Jickling G, Tari LW, Weiner JH and Taylor DE. (2000). J. Bacteriol., 182, 6509-6513.
40. Loennechen T, Utsi E, Hartz I, Lysaa R, Kildalsen H and Aarbakke J. (2001). Clin. Pharmacol. Ther., 70, 183-188.
41. Loennechen T, Yates CR, Fessing M, Relling MV, Krynetski EY and Evans WE. (1998). Clin. Pharmacol. Ther., 64, 46-51.
42. Lowenthal A, Meyerstein N and Ben Zvi Z. (2001). Eur. J. Clin. Pharmacol., 57, 43-46.
43. McDonald OG, Krynetski EY and Evans WE. (2002). Pharmacogenetics, 12, 93-99.
44. McLeod HL, Krynetski EY, Relling MV and Evans WE. (2000). Leukemia, 14, 567-572.
45. McLeod HL, Lin JS, Scott EP, Pui CH and Evans WE. (1994). Clin. Pharmacol. Ther., 55, 15-20.
46. McLeod HL, Miller DR and Evans WE. (1993). Lancet, 341, 1151.
47. McLeod HL, Relling MV, Liu Q, Pui CH and Evans WE. (1995). Blood, 85, 1897-1902.
48. Olson TS and Dice JF. (1989). Curr. Opin. Cell Biol., 1, 1194-1200.
49. Otterness D, Szumlanski C, Lennard L, Klemetsdal B, Aarbakke J, Park-Hah JO, Iven H, Schmiegelow K, Branum E, O'Brien J and Weinshilboum R. (1997). Clin. Pharmacol. Ther., 62, 60-73.
50. Otterness DM, Szumlanski CL, Wood TC and Weinshilboum RM. (1998). J. Clin. Invest, 101, 1036-1044.
51. Park-Hah JO, Klemetsdal B, Lysaa R, Choi KH and Aarbakke J. (1996). Clin. Pharmacol. Ther., 60, 68-74.
52. Pieters R, Huismans DR, Loonen AH, Peters GJ, Hahlen K, Van Der Does-Van Den Berg A, Van Wering ER and Veerman AJ. (1992). Int. J. Cancer, 51, 213-217.
53. Ranjard L, Prigent-Combaret C, Nazaret S and Cournoyer B. (2002). J. Bacteriol., 184, 3146-3149.
54. Relling MV, Hancock ML, Rivera GK, Sandlund JT, Ribeiro RC, Krynetski EY, Pui CH and Evans WE. (1999a). J. Natl. Cancer Inst., 91, 2001-2008.
55. Relling MV, Hancock ML, Rivera GK, Sandlund JT, Ribeiro RC, Krynetski EY, Pui CH and Evans WE. (1999b). J. Natl. Cancer Inst., 91, 2001-2008.
56. Relling MV, Rubnitz JE, Rivera GK, Boyett JM, Hancock ML, Felix CA, Kun LE, Walter AW, Evans WE and Pui CH. (1999c). Lancet, 354, 34-39.
57. Remy CN. (1963). J. Biol. Chem., 238, 1078-1084.
58. Remy CN. (1967). Biochim. Biophys. Acta, 138, 258-275.
59. Rossi AM, Bianchi M, Guarnieri C, Barale R and Pacifici GM. (2001). Eur. J. Clin. Pharmacol., 57, 51-54.
60. Scerri L. (1999). Adv. Exp. Med. Biol., 455, 343-348.
61. Schaeffeler E, Lang T, Zanger UM, Eichelbaum M and Schwab M. (2001). Clin. Chem., 47, 548-555.
62. Schutz E, Gummert J, Mohr F and Oellerich M. (1993). Lancet, 341, 436.
63. Schutz E, von Ahsen N and Oellerich M. (2000). Clin. Chem., 46, 1728-1737.
64. Seki T, Tanaka T and Nakamura Y. (2000). J. Human Genet., 45, 299-302.
65. Spire-Vayron dlM, Debuysere H, Fazio F, Sergent E, Bernard C Sabbagh N, Marez D, Lo Guidice JM, D'halluin JC and Broly F. (1999). Pharmacogenetics, 9, 189-198.
66. Spire-Vayron dlM, Debuysere H, Mastain B, Vinner E, Marez D, Lo Guidice JM, Chevalier D, Brique S, Motte K, Colombel JF, Turck D, Noel C, Flipo RM, Pol A, Lhermitte M, Lafitte JJ, Libersa C and Broly F. (1998). Br. J. Pharmacol., 125, 879-887.
67. Spire-Vayrone de la Mourneyre C, Debuysere H, Sabbagh N, Marez D, Vinner E, Chevalier ED, Lo Guidice JM and Broly F. (1998). Human Mutat., 12, 177-185.
68. Srivastava T, O'Neill JP, Dasouki M and Simckes AM. (2002). Am. J. Med. Genet., 108, 219-222.
69. Szumlanski C, Otterness D, Her C, Lee D, Brandriff B, Kelsell D, Spurr N, Lennard L, Wieben E and Weinshilboum R. (1996). DNA Cell Biol., 15, 17-30.
70. Szumlanski CL, Honchel R, Scott MC and Weinshilboum RM. (1992). Pharmacogenetics, 2, 148-159.
71. Tai HL, Fessing MY, Bonten EJ, Yanishevsky Y, d'Azzo A, Krynetski EY and Evans WE. (1999). Pharmacogenetics, 9, 641-650.
72. Tai HL, Krynetski EY, Schuetz EG, Yanishevski Y and Evans WE. (1997). Proc. Natl. Acad. Sci. USA, 94, 6444-6449.
73. Tai HL, Krynetski EY, Yates CR, Loennechen T, Fessing MY, Krynetskaia NF and Evans WE. (1996). Am. J. Hum. Genet., 58, 694-702.
74. Tatusov RL, Natale DA, Garkavtsev IV, Tatusova TA, Shankavaram UT, Rao BS, Kiryutin B, Galperin MY, Fedorova ND and Koonin EV. (2001). Nucleic Acids Res., 29, 22-28.
75. Van Loon JA and Weinshilboum RM. (1982). Biochem. Genet., 20, 637-658.
76. Weinshilboum R. (2001). Drug Metab. Dispos., 29, 601-605.
77. Weinshilboum RM, Adjei A, Johnson G and Otterness D. (1996). Thiopurine methyltransferase pharmacogenetics: inbred animal models, biochemical and molecular studies. Second Thiopurine Symposium, Hamburg.
78. Weinshilboum RM, Raymond FA and Pazmino PA. (1978). Clin. Chim. Acta, 85, 323-333.
79. Weinshilboum RM and Sladek SL. (1980). Am. J. Hum. Genet., 32, 651-662.
80. White SD, Rosychuk RA, Outerbridge CA, Fieseler KV, Spier S, Ihrke PJ and Chapman PL. (2000). J. Vet. Intern. Med., 14, 499-502.
81. Wielinga PR, Reid G, Challa EE, Van DH, I van Deemter L, de Haas M, Mol C, Kuil AJ, Groeneveld E, Schuetz JD, Brouwer C, De Abreu RA, Wijnholds J, Beijnen JH and Borst P. (2002). Mol. Pharmacol., 62, 1321-1331.
82. Wijnholds J, Mol CA, van Deemter L, de Haas M, Scheffer GL, Baas F, Beijnen JH, Scheper RJ, Hatse S, De Clercq E, Balzarini J and Borst P. (2000). Proc. Natl. Acad. Sci. USA, 97, 7476-7481.
83. Woodson LC, Dunnette JH and Weinshilboum RM. (1982). J. Pharmacol. Exp. Ther., 222, 174-181.
84. Woodson LC and Weinshilboum RM. (1983). Biochem. Pharmacol., 32, 819-826.
85. Yan L, Zhang S, Eiff B, Szumlanski CL, Powers M, O'Brien JF and Weinshilboum RM. (2000). Clin. Pharmacol. Ther., 68, 210-219.
86. Yates CR, Krynetski EY, Loennechen T, Fessing MY, Tai HL, Pui CH, Relling MV and Evans WE. (1997). Ann. Intern. Med., 126, 608-614.